- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Dementia
- Interventions
- 18F-MK6240, 18F-Florbetaben (FBB)
- Drug
- Lead sponsor
- Patrick Lao
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 707
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Severe Alzheimer Disease
- Interventions
- GRF6019, Placebo
- Drug · Other
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 60 Years to 95 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 3 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Centella asiatica product, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alzheimer Disease
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Santa Monica, California
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- All Subjects
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer's Disease
- Interventions
- Elenbecestat, Placebo
- Drug
- Lead sponsor
- Eisai Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 2,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 88
- States / cities
- Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease 1
- Interventions
- Aducanumab, Exablate Model 4000 Type 2, Lecanemab
- Drug · Device
- Lead sponsor
- Ali Rezai
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Apathy, Alzheimer's Disease
- Interventions
- Methylphenidate, placebo, Psychosocial intervention
- Drug · Other
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Charleston, South Carolina
- Conditions
- Alzheimer Disease
- Interventions
- LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- Trontinemab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 12
- States / cities
- Irvine, California • Long Beach, California • Oakland, California + 8 more
- Conditions
- Alzheimer Disease
- Interventions
- 11C-ER176, Florbetaben
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- Probiotic, Placebo
- Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Interventions
- Mobile Phone Application Assessments, Standard Assessments
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, Bepranemab
- Other · Biological
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 40
- States / cities
- Fresno, California • Fullerton, California • Irvine, California + 34 more
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 806 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
- Conditions
- Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
- Interventions
- Multimodal Lifestyle Intervention
- Behavioral
- Lead sponsor
- HudsonAlpha Institute for Biotechnology
- Other
- Eligibility
- 65 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Alzheimer's Disease
- Interventions
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Interventions
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Dementia, Alzheimer's Type, Alzheimer's Disease
- Interventions
- SAR448851, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Oakland, California • Naples, Florida • The Villages, Florida + 5 more
- Conditions
- Memory Disorders, Alzheimer's Disease
- Interventions
- Aricept, IFN-alpha2A
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mild Cognitive Impairment, Mild Alzheimer's Disease
- Interventions
- PET scan & fMRI
- Other
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Alzheimer's Disease
- Interventions
- TB006
- Drug
- Lead sponsor
- TrueBinding, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- San Diego, California • Delray Beach, Florida • Lady Lake, Florida + 7 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Pamlab, Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more